Archives for June 2020

Delhi on Monday emerged as the second worst-hit state by COVID-19 caseload in addition to death count though Chief Minister Arvind Kejriwal said the situation in the national capital was getting stabilised gradually while Goa reported its first fatality from the disease.

Coronavirus Cases Updates: Delhi recorded 2,909 fresh cases on Monday

India has added 14,933 new COVID-19 cases, pushing the infection tally to 4,40,215 while the death count rose to 14,011 with 312 new fatalities in the last 24 hours, data from the Union Health Ministry this morning showed. Delhi on Monday emerged as the second worst-hit state by COVID-19 caseload in addition to death count though Chief Minister Arvind Kejriwal said the situation in the national capital was getting stabilised gradually while Goa reported its first fatality from the disease.
 

More than nine million people have now been infected with the coronavirus worldwide, according to an AFP tally drawing on official sources, as of Monday 1520 GMT. More than half of the 9,000,091 cases are in Europe and the United States: Europe having recorded 2,537,451 and the United States 2,281,903. The number of cases worldwide has doubled since May 16 and more than a million new cases have been recorded in the past seven days. The official figures nevertheless reflect only a fraction of the true number, as many countries only test serious cases.

The Tamil Nadu government is giving special attention to coronavirus testing, Health Minister C Vijayabaskar said.

K Palaniswami was tested for coronavirus in strict adherence to testing protocols in Tamil Nadu

Tamil Nadu Chief Minister K Palaniswami has tested negative for coronavirus, Health Minister C Vijayabaskar said in Chennai today.

The government is giving special attention to coronavirus testing, he said adding that following protocol “without any exception, the chief minister subjected himself to the coronavirus testing and today we have the good news that he is negative.”

He maintained that the government was transparent in tackling coronavirus and no information was concealed and daily bulletins, district wise data are also being released.

Favipiravir being manufactured by Glenmark will be marketed by the name of Fabiflu and will be available in strength of 200 milligrams.

Glenmark Pharmaceuticals shares surged more than 35 per cent to a new 52-week high on Monday, after the company said it had received an approval from the government’s drug regulator to market and manufacture oral antiviral drug Favipiravir for treating mild to moderate COVID-19 patients in the country. On the BSE, Glenmark Pharma shares soared to as high as Rs 572.70 in the first half of the session, compared to their previous close of Rs 409.10.

The Mumbai-based drug maker said the clearance by the drug regulator was part of the government’s Accelerated Approval Process, which takes into account the disease severity, rarity, and the availability or lack of alternative treatment. Glenmark said the drug would be for “restricted emergency use” in the country.

A generic version of Favipiravir will be manufactured and marketed by Glenmark under the name Fabiflu, and will be available in the strength of 200 milligrams. Glenmark has priced the strip of 34 tablets at Rs 3,500, costing around Rs 103 per tablet, the company said in a regulatory filing.

Use of Favipiravir has been approved by medical authorities in China, Japan, Canada and Saudi Arabia among other countries.

India has over 4.25 lakh coronavirus cases, recording the biggest single-day jump of 445 deaths amid renewed concerns over the rapid rise in new infections in the country. The spike in cases has taken the country’s tally to 4,25,282 while the death count rose to 13,699, according to the Union Health Ministry data till Monday morning.

The coronavirus cases in Delhi have increased to 59,746. All coronavirus patients in Delhi will have to go to COVID-19 care centres and those who have facilities at home and have no co-morbidity can avail home isolation in the capital, the Centre said, hours after the Delhi government issued a revised order on home quarantine.

At 11:35 am, Glenmark shares traded 38.11 per cent higher at Rs 565.00 on the BSE, outperforming the benchmark Sensex index which was up 0.40 per cent.

The state government has already declared Morlem village, which falls under Valpoi, the Assembly constituency of Vishwajit Rane, as a COVID-19 containment zone.

Till Sunday, Goa reported 818 COVID-19 cases. Of these, 683 are active cases

An 85-year-old woman, who tested positive for coronavirus earlier, succumbed to the infection on Monday, making it the first case of death due to the viral disease in the state, Health Minister Vishwajit Rane said.

The woman, belonging to Morlem village in North Goa district, was undergoing treatment at the ESI hospital, a designated facility for COVID-19 patients, he said.

The state government has already declared Morlem village, which falls under Valpoi, the Assembly constituency of Vishwajit Rane, as a COVID-19 containment zone.

“Today, an 85-year-old woman from Morlem village died. This is the first COVID-19 death in the state. My condolences to the family,” Vishwajit Vishwajit Rane told reporters.

He said the state government was following all the latest protocols to keep Goa safe.

“Team Goa is united and is doing its best. Stringent methods and protocols are in place. The death was unfortunate, he said.

Vishwajit Rane appealed to people to remain calm and said the Goa government was making all efforts to contain the spread of COVID-19 in the state.

Till Sunday, Goa reported 818 COVID-19 cases. Of these, 683 are active cases.

Cipla shares surged over 9% after it got an approval from DCGI to manufacture and market generic COVID-19 drug Remdesivir.

Cipla shares surged over 9 per cent to hit a record high on Monday, after the company informed stock exchanges that it had received an approval from the government’s Drug Controller General of India (DCGI) to manufacture and market a generic version of Gilead Sciences’s experimental COVID-19 treatment Remdesivir. Cipla said its generic version of Remdesivir will be called Cipremi. Gilead Sciences signed non-exclusive licensing pacts last month with five generic drug makers based in India and Pakistan to expand the supply of its COVID-19 treatment.

“The US drug regulator issued an Emergency Use Authorization (EUA) to Gilead Sciences Inc. for emergency use of Remdesivir for the treatment of hospitalized 2019 coronavirus disease (COVID-19) patients. It is the only U.S. FDA approved Emergency Use Authorisation (EUA) treatment for adult and pediatric patients hospitalized with suspected or laboratory confirmed COVID-19 infection,” the Mumbai-based drug maker said in its regulatory filing.

India has over 4.25 lakh coronavirus cases, recording the biggest single-day jump of 445 deaths amid renewed concerns over the rapid rise in new infections in the country. The spike in cases has taken the country’s tally to 4,25,282 while the death count rose to 13,699, according to the Union Health Ministry data this morning.

The coronavirus cases in Delhi has neared the 60,000 mark, with 59,746 cases. 3,000 people tested positive on Sunday. All coronavirus patients in Delhi will have to go to COVID-19 care centres and those who have facilities at home and have no co-morbidity can avail home isolation in the capital, the centre said, hours after the Delhi government issued a revised order on home quarantine.

At 10:35 am, Cipla shares traded 3.33 per cent higher at Rs 658 on the BSE, outperforming the benchmark Sensex index which was up 0.70 per cent.